One clinical trial, two subjects, supporting one NDA

Regulators' comfort zone being tested

Prime Medicine says it will seek accelerated U.S. approval for PM359 — a gene‑editing, ex‑vivo therapy for chronic granulomatous disease (CGD) — on the basis of 1/2‑phase data from just two patients. CEO Allan Reine reportedly told investors that “based on recent communications with the FDA, Prime Medicine believes that the clinical data to date may be sufficient to support accelerated approval of PM359.” The move pushes at the boundary of how far regulators will accept ultra‑small datasets for ultra‑rare diseases.

The drug and the evidence

PM359 uses Prime Editing to correct NCF1 mutations in hematopoietic stem cells, restoring NADPH oxidase activity and, in early results, driving neutrophil engraftment within weeks and sustained enzyme activity for at least six months. It has been reported that the company initially planned a larger cohort — up to 12 patients with $20–30 million in investment — but scaled back after internal estimates suggested only ~50 U.S. patients would meet eligibility, and the program was deprioritized as the company refocused on in‑vivo liver‑targeted gene editing. Reportedly, that reprioritization contributed to workforce reductions in 2025.

Policy tailwinds and market incentives

Prime’s bid comes amid explicit FDA moves to accommodate “personalized” and ultra‑rare therapies. The agency’s February 2026 framework clarifies pathways for small‑n development when traditional randomized trials are infeasible. There is precedent: Xuriden was approved in 2015 on data from four patients. Economic incentives amplify the signal — the U.S. rare pediatric disease priority review voucher (PRV) program was extended through 2029, and PRVs have lately fetched well over $100 million in secondary markets, creating a strong commercial rationale for targeting ultra‑rare indications.

A shortcut or necessary flexibility?

If PM359 wins accelerated approval on two‑patient data, will that become a template — a faster route to market for life‑changing but commercially tiny therapies, or a lowering of evidentiary standards with attendant risks? Regulators argue flexibility is needed for conditions with vanishingly small populations. Critics will ask whether safety and durability can be judged on so few cases. Prime’s push is both a test case for policy and a reminder that regulatory incentives and market economics are reshaping how the industry approaches the rarest diseases.